This website uses cookies to enhance the user experience.
R

RUNDE MILJØSENTER AS987 410 752

Research
Limited company
Runde 6096 RUNDE, Norge

RUNDE MILJØSENTER AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
20 years
since Nov 1, 2004
Type
Limited company
VAT registered
Yes
Number of employees
13

Ownership

Number of shares and share classes
50,000
1 share class
Total number of shareholders
5
2 companies, 3 persons
Belongs to group of

Financials

Total operating income 2023
10,541,604
NOK
Annual total result 2023
-504,863
NOK
Total equity 2023
826,539
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Board Member
20 %
directly
Board Member-
Chairman-
Board Member-
Board Member-
Board Member-

Others

NameRoleShares
B
BDO AS
Auditor-
D
DRIV ØKONOMI AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Board Member
20 %
directly
-
20 %
directly
-
20 %
directly
Last update: Oct 23, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
R
RUNDE MILJØSENTER AS
Ordinary shares
10,000
20 %
Ordinary shares
10,000
20 %
Ordinary shares
10,000
20 %
Ordinary shares
10,000
20 %
Ordinary shares
10,000
20 %

Shares owned by the RUNDE MILJØSENTER AS

NameShare classNumber of sharesShare
O
OPPLEV RUNDE AS
Ordinary shares
30,000
100 %
R
RUNDE FORSKING AS
Ordinary shares
30,000
93.46 %
R
RUNDE MILJØSENTER AS
Ordinary shares
10,000
20 %
R
RUNDE MILJØBYGG AS
Ordinary shares
8,200
3.73 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 10,541,604
    Operating profit 2023: NOK -392,018
    Employees: 13

Financials

in NOK

Summary

Year202320222021
Total operating income
10,541,604
10,261,642
9,460,066
Annual Total Result
-504,863
301,120
47,537
Total assets
7,570,430
6,179,408
3,795,134
Total liabilities
6,743,891
4,848,006
2,564,852
Total equity
826,539
1,331,402
1,230,282

P&L

Year202320222021
Total operating income
10,541,604
10,261,642
9,460,066
Total operating costs
10,933,622
9,764,890
9,385,403
Operating result
-392,018
496,752
74,664
Financial income/costs
-254,217
-109,855
-9,455
Profit before tax
-646,236
386,896
65,208
Total tax & extraordinary income/cost
-141,373
85,776
17,671
Annual Total Result
-504,863
301,120
47,537

Balance overview

Year202320222021
Total fixed assets
4,620,500
4,165,057
1,599,847
Total current assets
2,949,930
2,014,351
2,195,287
Total assets
7,570,430
6,179,408
3,795,134
Short term debt
4,574,371
2,600,612
2,564,852
Long term debt
2,169,520
2,247,394
0
Total liabilities
6,743,891
4,848,006
2,564,852
Contributed capital
826,539
834,536
934,536
Retained earnings
0
496,866
295,746
Total equity
826,539
1,331,402
1,230,282
Total equity and liabilities
7,570,430
6,179,408
3,795,134

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology